Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors
Citation, DOI, disclosures and article data
At the time the article was created Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
At the time the article was last revised Yuranga Weerakkody had no recorded disclosures.View Yuranga Weerakkody's current disclosures
Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors which often go under the name palbociclib, ribociclib, and abemaciclib are used in patients with hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−) advanced breast cancer.
CDK 4 and CDK 6 are downstream agents in the estrogen signaling pathway which control entry into the cell cycle. This inhibition is thought to prevent tumor cell progression in the cell cycle.
- 1. Shah A et.al. The Growing Role of CDK4/6 Inhibitors in Treating Hormone Receptor-Positive Advanced Breast Cancer. (2017) Current treatment options in oncology. doi:10.1007/s11864-017-0443-7 - Pubmed
- 2. Cersosimo R, Cersosimo. Cyclin-dependent kinase 4/6 inhibitors for the management of advanced or metastatic breast cancer in women. (2019) American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists. doi:10.1093/ajhp/zxz121 - Pubmed
- 3. Ramos N et.al. Noninvasive PET Imaging of CDK4/6 Activation in Breast Cancer. (2020) Journal of nuclear medicine : official publication, Society of Nuclear Medicine. doi:10.2967/jnumed.119.232603 - Pubmed
- 4. Kwapisz D. Cyclin-dependent kinase 4/6 inhibitors in breast cancer: palbociclib, ribociclib, and abemaciclib. (2017) Breast cancer research and treatment. doi:10.1007/s10549-017-4385-3 - Pubmed